+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Preventing lactic acidosis in HIV HCV coinfected patients during interferon and ribavirin treatment Development of a real time PCR for mitochondrial DNA copy number in PBMCs



Preventing lactic acidosis in HIV HCV coinfected patients during interferon and ribavirin treatment Development of a real time PCR for mitochondrial DNA copy number in PBMCs



Hepatology 36(4 Part 2): 230A




Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 035550468

Download citation: RISBibTeXText


Related references

Report of three cases of hyperlactacidemiae/lactic acidosis after treatment of hepatitis C with pegylated interferon and ribavirin in HIV coinfected patients. Revista Clinica Espanola 202(10): 543-545, 2002

High risk of lactic acidosis in HIV-HCV coinfected patients under HAART and treated by the combination of interferon and ribavirin. Hepatology 36(4 Part 2): 592A, 2002

Real life experience in treatment of HIV-1/HCV-coinfected patients with pegylated interferon alpha and ribavirin: predictors of SVR. New Microbiologica 38(1): 21-27, 2015

Thyroid alterations following treatment with pegylated interferon and ribavirin: differences between HIV-coinfected and non-coinfected patients. Enfermedades Infecciosas Y Microbiologia Clinica 24(3): 213-214, 2006

Short communication: Interferon/ribavirin treatment for HCV is associated with the development of hypophosphatemia in HIV/hepatitis C virus-coinfected patients. Aids Research and Human Retroviruses 29(9): 1190-1194, 2013

Copy number of bean mitochondrial genes estimated by real-time PCR does not correlate with the number of gene loci and transcript levels. Plant Molecular Biology 61(1-2): 1-12, 2006

Risk factors for symptomatic mitochondrial toxicity in HIV/hepatitis C virus-coinfected patients during interferon plus ribavirin-based therapy. Journal of Acquired Immune Deficiency Syndromes 40(1): 47-52, 2005

HCV clearance from saliva of HIV-HCV-coinfected patients on treatment with interferon plus ribavirin. Oral Diseases 20(3): 313-318, 2014

Hcv clearance from saliva of hiv-hcv coinfected patients on treatment with interferon plus ribavirin. 2013

Immune responses to hepatitis C virus proteins by PBMCs from patients responding to treatment with interferon + ribavirin. Hepatology 30(4 Part 2): 452A, 1999

Changes in T-cell subsets in HIV-HCV-coinfected patients during pegylated interferon-alpha2a plus ribavirin treatment. Antiviral Therapy 15(3): 333-342, 2010

Pegylated interferon alpha-2b plus ribavirin for the treatment of chronic hepatitis C in HIV-coinfected patients. Journal of Infection 53(1): 36-42, 2006

Autoimmune hemolytic anemia in HCV/HIV coinfected patients during treatment with pegylated alpha-2a interferon plus ribavirin. Revista Da Sociedade Brasileira de Medicina Tropical 40(6): 678-680, 2008

CD81 expression in peripheral blood lymphocytes before and after treatment with interferon and ribavirin in HIV/HCV coinfected patients. HIV Medicine 11(3): 161-169, 2010

Alpha-interferon versus peg-interferon associated to ribavirin in the treatment of genotype 1 hepatitis C virus and human immunodeficiency virus coinfected patients. Arquivos de Gastroenterologia 46(2): 132-137, 2009